A Study of Sequential Therapy With AHB-137 Injection Followed by TVAX-008 Injection in Participants Living With Chronic Hepatitis B (CHB)

• Voluntarily participate in the study and sign the informed consent form, and comply with the requirements of the study protocol;
• 18-65 years of age (including boundary values) for men or women;
• Body mass index met the requirements;
• HBeAg negative at screening;
• Meet the relevant requirements for prior medications;
• HBsAg and HBV DNA and liver function indicators meet the requirements;
• Use contraception as required;

Exclusion Criteria:

• Uncontrolled and stable clinically significant abnormalities or other serious diseases other than a history of chronic HBV infection;
• Has received treatment with the relevant medication;
• Participants with clinically significant relevant liver diseases, manifestations of liver function decompensation, history of extrahepatic diseases related to HBV immune status, liver fibrosis or cirrhosis, and confirmed or suspected liver cancer;
• Any serious infection other than chronic hepatitis B infection requires intravenous anti-infective therapy;
• HCV RNA positive, HIV antibody positive, syphilis positive within 12 months;
• Abnormal laboratory results;
• Diseases associated with vascular inflammatory conditions;
• QT interval corrected heart rate (Fridericia method) abnormal;
• History of malignancy or ongoing assessment of possible malignancy;
• History of allergies, or allergic constitution;
• Recent major trauma or major surgery, or planned surgery;
• Those who are participating in another clinical trial, or have not undergone a protocol-specified washout period prior to this study;
• Prior/current use of prohibited medications;
• Thyroid function abnormal;
• There are serious cardiovascular and cerebrovascular diseases;
• Inappropriate for participation in this trial as judged by the investigator.